<DOC>
	<DOCNO>NCT01331694</DOCNO>
	<brief_summary>To evaluate COPD-related clinical outcome total healthcare utilization commercially insured ( least 40 year subanalysis age 65 year old ) COPD population associate use fluticasone/salmeterol combination ( FSC ) 250/50mcg compare initial maintenance therapy ( IMTs ) , specifically , tiotropium bromide ( TIO ) , either ipratropium bromide ipratropium bromide/albuterol ( IP ) . This hypothesis test study Ho : There difference time first COPD-related event FSC TIO FSC IP Ha : There difference time first COPD-related event FSC TIO FSC IP Hypothesis key secondary outcome COPD-related cost test : Ho : There difference COPD-related cost FSC TIO FSC IP Ha : There difference COPD-related cost FSC TIO FSC IP</brief_summary>
	<brief_title>Outcomes Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination ( FSC ) Versus Anticholinergics Including Tiotropium ( TIO ) Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>All population i.e . least 40 year : Each initial maintenance treatment ( IMT ) cohort ( FSC 250/50mcg dose , IP , TIO ) include patient age 40 year old least 9 month continuous enrollment ( 6 month pre-index least three month post-index ) primary secondary diagnosis COPD [ International Classification Disease , 9th revision , Clinical Modification ( ICD-9-CM ) cod 491.xx , 492.xx 496.xx ] . Patients observe everyone provide minimum 6 month pre index baseline data minimum 3 month post index ( risk analysis ) minimum 12 month post index cost analysis . Patients must receive either 30-day supply FSC IP TIO initial IMT medication , indicate `` intent treat . '' Patients may also prescription fill IMT medication within 60 day index date , combination therapy budesonide/ formoterol ( BFC ) , inhale corticosteroid ( ICS ) long act beta agonist ( LABA ) . Six month observation ( continuous enrollment ) prior index date assess confirm patient meet inclusion exclusion criterion well identify baseline characteristic covariates . Cost analysis do use 12 month fix follow period . Outcome measure assess post-index period Elderly cohort 65+ : Identical method design use subanalyses patient age 65 year except comparison FSC vs. TIO . 75+ cohort : Identical method design use subanalyses patient age 75 year except comparison FSC vs. TIO .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Inclusion Criteria IMT Cohorts ( subject select order criterion ) claim one study medication must receive another study medication within 60 day initial maintenance therapy , indicate `` intent treat . '' least one COPDrelated ED one COPDrelated hospitalization , two COPDrelated outpatient visit ( OV ) associate primary secondary diagnosis COPD ( ICD9CM code 491.xx , 492.xx 496.xx ) , time observation period ( July 1 , 2005 June 30 , 2008 ) database . Aged 65+ year index date age 40 subanalysis . Continuous enrollment health plan least 6 month prior ( preindex ) initiation IMT least three month first initiation IMT ( postindex ) . least one prescription claim preindex year postindex period followup . Exclusion Criteria All Cohorts primary secondary diagnosis respiratory tract cancer ( larynx , trachea , pleura ) . ( ICD9CM cod 161 , 161.X , 162 , 163 , 163.X , 231 , 231.X ) . In preindex period , claim cohort IMT medication , Advair budesonide/formoterol fix dose combination , FSC combination medication , may respiratory medication pharmacy claim drug include preindex severity illness assessment ( Methylxanthines , Leukotriene Modifiers/Inhibitors , Omalizumab Mast Cell Stabilizers ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>